Analytikerkommentar
Gubra – Boehringer Ingelheim's Triple Agonist BI 3034701 to Enter Phase 2 in Mid-2026
Oversigt
- Gubra announced that Boehringer Ingelheim plans to start Phase 2 development of the triple agonist BI 3034701 for obesity in mid-2026, highlighting Gubra's platform capabilities.
- Boehringer Ingelheim holds full responsibility for the global clinical development and commercialization of BI 3034701, with Gubra eligible for milestone payments and royalties.
- The progression to Phase 2 is seen as a potential revenue trigger for Gubra, although specific milestone amounts have not been disclosed.
- While BI 3034701's advancement is positive, ABBV-295 and the UCN2 program are considered the primary value drivers, with significant developments expected in 2026.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Gubra today announced that its partner Boehringer Ingelheim plans to initiate Phase 2 development of BI 3034701 in mid-2026. BI 3034701 is a potential first-in-class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity, originating from Gubra's peptide discovery platform. The advancement provides further validation of Gubra's platform capabilities - particularly its ability to engineer differentiated, first-in-class peptide candidates within obesity that attract continued development investment from top-tier pharma partners.
Under the existing collaboration and license agreement, Boehringer retains full responsibility for global clinical development and commercialisation, with Gubra eligible for downstream milestone payments and royalties on net sales. While specific milestone amounts tied to the Phase 2 initiation have not been disclosed, the progression to mid-stage development typically represents a milestone trigger in biotech partnerships, providing potential near-term revenue. Gubra has historically not provided revenue guidance for its Biotech segment, given the inherent timing uncertainty around partnership milestones.
The advancement is incrementally positive for the broader portfolio. A successful Phase 2 readout for BI 3034701 in due course would further validate Gubra's discovery engine and increase the strategic attractiveness of its remaining partnered and proprietary assets. That said, ABBV-295 (out-licensed to AbbVie) and the wholly-owned UCN2 program remain the primary value drivers in our model and research, with Phase 2 progression for ABBV-295 expected later in 2026 and first human data from UCN2 anticipated in H1 2026 - the two most material near-term catalysts for the investment case.
Disclaimer: HC Andersen Capital receives payment from Gubra for a DigitalIR subscription agreement. / Philip Coombes 15:27 28/04-2026